PAX1 and cervical cancer: Detection of high‐grade cervical lesions in patients with atypical squamous cells of undetermined significance (ASCUS) remains a challenge in the screening and diagnosis of cervical cancer. PAX1 methylation demonstrated better performance as a marker than results of a high‐risk HPV‐DNA test for the detection of high‐grade lesions (CIN2+) in ASCUS cases; however, PAX1 methylation allows for the screening out of a majority of low‐grade ASCUS cases (Li et al., 2015; Wang, 2014).